Of sensible relevance to the problem of MS therapy and identification of disease pathogenesis is the finding that Glatiramer acetate (GA), alone or in combination with IFNβ, is able to down-regulate CD1 expression in vitro or in vivo. The gene discussed is IFNB1; the disease is myeloid sarcoma.